SCHEMBL15611171

SCHEMBL15611171

COc1cc(OC)cc(-c2nc3cnc(Nc4c(C)cccc4N)nc3n(C)c2=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 2/20 0.59
▸ CYP1A2 P05177 18/20 0.58
▸ USP2 O75604 16/20 0.58
▸ MEN1 O00255 11/20 0.58
▸ KMT2A Q03164 11/20 0.58
▸ CASP7 P55210 11/20 0.58
▸ CASP1 P29466 10/20 0.58
▸ ALDH1A1 P00352 9/20 0.58
▸ LMNA P02545 4/20 0.58
▸ MAPK1 P28482 3/20 0.58
▸ CLK4 Q9HAZ1 2/20 0.58
▸ CYP3A4 P08684 6/20 0.51
▸ HIF1A Q16665 4/20 0.51
▸ TP53 P04637 3/20 0.51
▸ HSD17B10 Q99714 3/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.50
▸ BRCA1 P38398 2/20 0.47
▸ HBB P68871 1/20 0.47
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15434027 0.83 FGFR1 (0.54) FGFR4CYP1A2USP2MEN1KMT2A
SCHEMBL20705982 0.79 FGFR1 (0.49) FGFR4CYP1A2USP2MEN1KMT2A
SCHEMBL22420120 0.77 FGFR4 (0.80) FGFR4CYP1A2USP2MEN1KMT2A
SCHEMBL16071795 0.74 FGFR4 (1.00) FGFR4CYP1A2USP2MEN1KMT2A
SCHEMBL15434002 0.73 FGFR4 (0.49) FGFR4CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL16134080 0.73 FGFR4 (0.74) FGFR4CYP1A2USP2MEN1KMT2A
SCHEMBL15413109 0.73 CYP1A2 (0.58) FGFR4CYP1A2USP2MEN1KMT2A
SCHEMBL7689910 0.72 USP2 (0.81) CYP1A2USP2MEN1KMT2ACASP7
SCHEMBL15413093 0.72 FGFR1 (0.72) FGFR4
SCHEMBL15413641 0.70 FGFR4 (0.40) FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2872491-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2021-05-05 — — EP disclosed
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-02-05 — — US disclosed
US-20180362613-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2018-12-20 — — US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed
US-9340514-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2016-05-17 — — US disclosed
US-9126951-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2015-09-08 — — US disclosed
US-20150210694-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-07-30 — — US disclosed
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-12-25 — — US disclosed
US-8802697-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2014-08-12 — — US disclosed
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-07-03 — — US disclosed
US-20140088100-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210694-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885CYP1A2 4751/4885USP2 3486/4885
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor FGFR1, FGFR2, FGFR3 FGFR4 5/4885CYP1A2 4751/4885USP2 3486/4885
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885CYP1A2 4751/4885USP2 3486/4885
US-20140088100-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885CYP1A2 4751/4885USP2 3486/4885
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885CYP1A2 4751/4885USP2 3486/4885
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885CYP1A2 4751/4885USP2 3486/4885
US-20180362613-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885CYP1A2 4751/4885USP2 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback